Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis TranscriptSeeking Alpha · 16 hr ago
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B OpportunityMarketBeat · 19 hr ago
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinibReuters · 1 day ago
Novartis' breast cancer drug cuts risk of death by 19% after six years, data showsReuters · 1 day ago
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key MetricsZacks Investment Research · 2 days ago
Novartis: The Sell-Off Creates An Attractive Entry PointSeeking Alpha · 5 days agoNovartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 21, 2026 | $2.17 | $2.41 | Beat |
| Apr 28, 2026 | $2.11 | $1.99 | Miss |
| Feb 4, 2026 | $1.99 | $2.03 | Beat |
| Oct 28, 2025 | $2.26 | $2.25 | Miss |
| Jul 17, 2025 | $2.38 | $2.42 | Beat |
| Apr 29, 2025 | $2.12 | $2.28 | Beat |